2023-03-21| Policy

HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices

by Richard Chau
Share To
For the very first time in history, Medicare will be able to negotiate lower prescription drug prices since the passage of the Inflation Reduction Act by Congress last August and its signing by President Joe Biden.

The U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), issued initial guidance on March 15 that details the requirements and parameters associated with crucial elements of the new Medicare Drug Price Negotiation Program and includes requests for public comment. The new negotiated prices will apply for the first time in 2026.

According to Xavier Becerra, Secretary of HHS, “Through the Medicare Drug Price Negotiation Program, we will make sure seniors get a fair price on Medicare’s costliest prescription drugs, promote competition in the market, and ensure Medicare is strong for beneficiaries today and into the future.”

It's free! Log in now to read

From Sweet to Risky: The Alarming Findings on Sucralose’s Genotoxicity
GHG Emissions as a ESG Metric
NSTC Joins Forces with Taiwan Biomedical Start-ups to Rise to the World Stage, Showcasing Innovations at US BIO’s Demo Day
Krystal Biotech’s First Topical Gene Therapy Approved by FDA
The Emergence of General AI for Medicine: Medical Applications of ChatGPT
Strengthening Genetic Screening Platform in APAC for Lung Cancer Precision Medicine: An Interview with Dr. Koichi Goto
2023 International Healthcare Week: Showcasing Emerging Competencies of Hong Kong’s Biomedical Industry
Scroll to Top